Introduction {#Sec1}
============

Posterior fossa tumors showing neuronal and glial differentiation, with or without a ganglion component, have been described in recent years \[[@CR1]\]. Rosette-forming glioneuronal tumor (RGNT) of the fourth ventricle (WHO grade I), a rare slow growing tumor affecting mainly the young, characterized by distinct neurocytic rosettes or perivascular pseudorosettes and an astrocytic component, is one of the rare benign mixed neuronal-glial neoplasms added in the most recent edition of *WHO Classification of Central Nervous System (CNS) Tumors* (2007) \[[@CR2]\]. It was first described as a dysembryoplastic neuroepithelial tumor (DNET) of the cerebellum in 1995 \[[@CR3]\] and was recognized as a new entity in 2002, largely based on the reports of Komori et al*.* who extensively described 11 cases \[[@CR4]--[@CR6]\]. RGNT was initially described as occurring solely in the fourth ventricle and with possible extension into the surrounding structures, including the cerebellar vermis, cerebello-pontine angle, midbrain and aqueduct of Sylvius \[[@CR4], [@CR7], [@CR8]\]. However, reports of origin from other sites in the CNS, including the pineal region, have been documented \[[@CR4], [@CR9]\]. Scheithauer et al*.* \[[@CR10]\] described RGNT in the optic chiasm in a 23-year-old Caucasian male with neurofibromatosis Type 1 (NF1). It was also reported in the cervical spinal cord of a 44-year-old woman \[[@CR11]\]. Recently, an unusual widespread intraventricular dissemination of RGNT was described in a 16-year-old Chinese girl with stable outcome 7 months post-radiotherapy \[[@CR12]\].

Consistently, reports show a high frequency of somatic isocitrate dehydrogenase 1 (IDH1) and isoform IDH2 mutation among oligodendrogliomas, astrocytomas and secondary glioblastomas \[[@CR13]--[@CR21]\]. This mutation is exceedingly rare in primary glioblastomas and pilocytic astrocytomas, and virtually absent in meningiomas and ependymomas, suggesting a different pathobiological mechanism or stem cell glial precursor. In a limited study, IDH1 mutation in gangliogliomas was reported to be associated with poorer outcome, though IDH1-positive gangliogliomas showed "atypical" features pathologically \[[@CR20]\]. Whether these IDH1 mutant cases are diffuse gliomas with overrun neurons remains to be resolved. As RGNT shares some morphologic features with low grade gliomas and gangliogliomas, we carried out deoxyribonucleic acid (DNA) sequencing of IDH1 \[residue (R)132\] and IDH2 (R172) mutation hotspots to assess whether they also occur in this tumor.

Excluding this case, we identified 19 published papers with 43 diagnosed RGNT cases to date. The prevalence of some clinico-radiologic and histologic findings has not been quantified; hence, it is also the objective of this report to review the frequency of specific radiographic and histologic findings, as well as analyze treatment and outcome from previously-described cases to better elucidate the nature of this rare neoplasm.

Case summary {#Sec2}
============

A previously healthy 16-year old female presented for chronic episodes of right-sided headaches and vomiting, relieved with rest alone. On physical examination, her pupils were noted to be sluggishly reactive to light and bilateral papilledema was noted. Noncontrast computed tomographic study of the head revealed a mass centered in the pineal gland region with punctate calcification, extending into the posterior aspect of the third ventricle. There was marked associated obstructive hydrocephalus due to mass effect and compression of the cerebral aqueduct. A subsequent cranial magnetic resonance imaging (MRI) with gadolinium further defined a heterogeneous, non- enhancing 3.8 cm × 3.6 cm × 3 cm mass in the pineal region, encroaching into the posterior third ventricle (Fig. [1](#Fig1){ref-type="fig"}). MRI of the spine showed no metastatic disease. A biopsy of the tumor was performed via endoscopic third ventriculostomy. Tumor markers, including beta-human chorionic gonadotropin, and alpha-fetoprotein were not significantly elevated in both the blood and cerebrospinal fluid (CSF). The pathologic diagnosis was RGNT. The patient was referred for tumor debulking 8 weeks post-biopsy as follow-up MRI revealed increasing hydrocephalus. A suprasellar, infratentorial approach was undertaken and subtotal resection was achieved. Post-operatively, the patient showed significant improvement with no reported complications. Follow-up imaging 2 months post-resection revealed a residual mass in the pineal gland region with stable hydrocephalus. Of note, the patient has stable neurologic status and continues to see a pediatric endocrinologist for primary amenorrhea, which may be related to the chronic hydrocephalus.Fig. 1Preoperative MRI findings. **a** T1-weighted sagittal MRI shows a heterogenous predominantly isointense to slightly hypointense mass (*arrow*) centered in the pineal region and extending to the posterior aspect of the third ventricle. There is extensive associated mass effect, including upon the tectum, with effacement of the cerebral aqueduct. There is enlargement of the lateral and third ventricles due to obstructive hydrocephalus. Multiple hypointense foci within the tumor may indicate cystic areas. There is no extension of tumor to the fourth ventricle or cerebral aqueduct; **b** T1-weighted axial MRI with gadolinium shows no enhancement within the tumor

The review of RGNT cases was carried out through searches in the literature using PubMed queries (up to and including January 2010) for original articles (including reviews) using a combination of the terms *rosette forming glioneuronal tumor* and *RGNT*. The cited references of the sources were also searched. The search yielded 30 papers reporting a total of 43 RGNT cases. The pertinent clinical, radiographic and histological data are presented in tables and further elucidated in the discussion.

Materials and methods {#Sec3}
=====================

Histology and immunohistochemistry {#Sec4}
----------------------------------

Samples were fixed in 10% neutral formalin and paraffin-embedded sections were stained with hematoxylin and eosin for routine light microscopy. Immunohistochemical examinations on 5-micron thick sections were performed on both specimens using BenchMark XT (BMX), utilizing standard avidin--biotin-peroxidase complex technique and diaminobenzidine as chromogen with the following antibodies: glial fibrillary acidic protein (GFAP) (1:200, GF2 clone, monoclonal, DAKO), synaptophysin (Prediluted, 1:100, Ventana), neurofilament (NF) (pre-diluted, 2F11, monoclonal, DAKO), and Ki-67 (1:100, clone MIB-1, monoclonal, DAKO).

IDH1/2 mutation analysis {#Sec5}
------------------------

### DNA extraction {#Sec6}

DNA was extracted from the patient's resection specimen (FFPE) using the Recoverall Kit (Applied Biosystems/Ambion, Foster City, CA) according to manufacturer's directions.

### Polymerase Chain Reaction (PCR) amplification {#Sec7}

PCR reactions for IDH1 and 2 amplification employed similar methods published elsewhere \[[@CR15], [@CR18], [@CR19]\]. An IDH1 fragment of 237 bp in length spanning the sequence including codon 132 (exon 4) was amplified using forward 5´GCGTCAAATGTGCCACTATC3´and reverse 5´-5´GCAAAATCACATTATTGCCAAC3´ primers. An IDH2 fragment of 265 bp in length of IDH2 spanning codon 172 (exon 4) was amplified using forward 5´CTCACAGAGTTCAAGCTGAAGAAG3´ and reverse 5´CTGTGGCCTTGTACTGCAGAG3´ primers. PCR reactions were performed in 30 μl volume, including 20 ng of genomic DNA, 10 pmol of each forward and reverse primer above, 1× PCR buffer, 0.3 mM dNTP, 1.5 mM MgCl~2~ and 0.5 unit of Platinum Taq (Invitrogen, Carlsbad, CA). PCR conditions were: 94°C for 1 min and 30 s; 5 cycles of 94°C for 20 s, 65°C for 20 s, 72°C for 20 s; 5 cycles of 94°C for 20 s, 60°C for 20 s, 72°C for 20 s; 5 cycles of 94°C for 20 s, 55°C for 20 s, 72°C for 20 s; and 30 cycles of 94°C for 20 s, 50°C for 20 s, 72°C for 20 s, followed by 72°C for 10 min. 6 μl of PCR product was loaded on a 2% agarose gel and visualized under UV light.

### Sequencing detection {#Sec8}

The PCR products were purified using DNA Clean & Concentrator Kit (Zymo Research, Orange, CA). 10 ng of purified PCR product was used for sequencing reaction with total volume of 10 μl, containing 1.6 pmol of sequencing primers (IDH1 5´GCGTCAAATGTGCCACTATC3´ and IDH2 5´CTCACAGAGTTCAAGCTGAAGAAG3´), 1× sequencing buffer, 1.5 μl of BigDye Terminator v1.1(Applied Biosystems, Foster City, CA). Sequencing conditions were: 96°C for 1 min, followed by 25 cycles of 96°C for 10 s, 50°C for 5 s and 60°C for 4 min. The sequencing reactions were purified using Performa DTR Gel Filtration Cartridges (Edge Bio, Gaithersburg, MD) and analyzed on a 3730 sequencer (Applied Biosystems) maintained by the UCLA Sequencing Core.

Results {#Sec9}
=======

Histology and immunohistochemistry {#Sec10}
----------------------------------

Histologic examination of both biopsy and resection specimens revealed a biphasic, moderately cellular neoplasm (Fig. [2](#Fig2){ref-type="fig"}). The lesion was composed of a synaptophysin immunoreactive neurocytic component characterized by monomorphic cells with round hyperchromatic nuclei and scant cytoplasm forming rosettes and perivascular pseudorosettes, and an extensively GFAP positive piloid glial area similar to that in previously described RGNTs \[[@CR2]--[@CR12], [@CR22]--[@CR29]\]. Synaptophysin immunoreactivity was also noted in the eosinophilic cores of rosettes and perivascular rosettes formed by bland neurocytes. In areas of the glial component, tumor cells arranged in cords and packets with frequent peri-cellular halos resembling an oligodendroglioma were found. Focal microcalcifications were identified. Rosenthal fibers, eosinophilic granular bodies (EGBs), mitoses, necroses and vascular endothelial hyperplasia were not identified. Ki67 immunostain revealed a low proliferation index estimated at approximately 1% or less. Chromogranin stain was largely negative and did not reveal neoplastic ganglion cells.Fig. 2Histologic features: **a** Low power microscopy reveals a biphasic tumor with neurocytic (*right*) and astrocytic (*left*) components, H&E, ×200; **b** Well-formed perivascular rosettes and true rosettes (*inset*), H&E, ×1,000; **c** Strong synaptophysin staining is noted among neurocytes and neurocytic cores, ×400; **d** High power view of the synaptophysin-positive neurocytic cores, ×1,000; **e** Glial fibrillary acidic protein immunostain highlights the piloid astrocytic component, ×200; and **f** Collections of oligodendrocyte-like cells are present, H&E, ×400

IDH1 and 2 mutation analyses {#Sec11}
----------------------------

IDH analysis of this tumor showed wild type genetic sequences in exon 4 of both IDH1 (R132) and IDH2 (R172) genes.

Discussion {#Sec12}
==========

Epidemiology of this neoplasm is limited since there are relatively few published cases. In our review (Fig. [3](#Fig3){ref-type="fig"}), this tumor was found to more commonly afflict young adults (mean: 30 ± 12.8 years ), with nearly a two-fold female predominance (1.9:1 female to male ratio), which is similar to earlier findings \[[@CR4], [@CR24], [@CR29]\].Fig. 3Age distribution of rosette-forming glioneuronal tumor cases showing predominantly younger age group (11--40 age bracket). The mean age at presentation is 30.3 ± 12.8 years with 1.9:1 female to male ratio

The clinico-radiologic characteristics in our patient are similar to those previously described. However, this tumor largely involves the pineal region, abuts the posterior third ventricle and impinges on the cerebral aqueduct causing hydrocephalus, which is a less common observation. Table [1](#Tab1){ref-type="table"} summarizes the clinical findings from previously published data. Our patient presented with headache and vomiting which are still the most commonly reported symptoms in the review (Table [2](#Tab2){ref-type="table"}). Ataxia (39.5%), vertigo (16.3%), cranial nerve palsies (13.2%) and visual complaints (11.6%), are also commonly observed. Signs and symptoms appear to be related to the common location of this tumor (see Table [1](#Tab1){ref-type="table"}) which is the fourth ventricle (31.8%) and contiguous structures (25%), and are related to posterior fossa involvement and early development of obstructive hydrocephalus from CSF flow interruption in the fourth ventricle. Li et al*.* \[[@CR25]\] reported intratumoral hemorrhage in one patient leading to incidental diagnosis, along with five other cases that did not have apparent symptoms (14%).Table 1Summary of clinical and radiological features of rosette-forming glioneuronal tumor casesPatient demographics Age in years, mean (SD)30.3 (±12.8) Gender, *n* (%)  Male15/44 (39.5)  Female29/44 (60.5) Duration in months, mean (SD)27.2 (±44.8) Treatment, *n* (%)  GTR25/44 (56.8)  STR15/44 (34.1)  Biopsy5/44 (11.4)  Radiotherapy2/44 (4.5) Post-op morbidity, *n* (%)  Yes13/35 (37.1)  No^a^23/35 (65.7) Follow-up in months, mean (SD)30.2 (±35.7) Outcome, *n* (%)  Stable29/35 (94.3)  Death1/35 (2.9)  Recurrence1/35 (2.9)Radiologic features Location, *n* (%)  Fourth ventricle+25/44 (56.8)  Cerebellum10/44 (22.7)  Pineal4/44 (9.1)  Others5/44 (11.4) Size in mm, mean (SD)30.3 (±16.8) Findings, *n* (%)  Enhancement29/44 (65.9)  Cyst24/44 (52.5)  Hydrocephalus19/44 (43.2)  Calcification11/44 (25)  Satellite lesion7/44 (15.9)*SD* standard deviation, *NA* data not available, *GTR* gross total resection, *SRT* subtotal resection. Fourth ventricle+ refers to tumor originating from or centered in the fourth ventricle with involvement of the contiguous structures^a^Transient symptoms were includedTable 2Frequency of signs and symptoms observed in rosette-forming glioneuronal tumor casesSigns and symptomsFrequency (%)Headache27 (62.8)Ataxia17 (39.5)Vertigo7 (16.3)Nausea/vomiting7 (16.3)Cranial nerve palsy6 (14.0)Incidental6 (14.6)Visual complaints5 (11.6)Motor sensory4 (9.3)Dysarthria3 (7.0)Seizure1 (2.3)Nystagmus1 (2.3)Hyperacussis1 (2.3)

Paramount concern among studies of "new" tumor entities is in regard to their natural history. This tumor appears to have a variable growth pattern. Available data in 32 cases (Table [1](#Tab1){ref-type="table"}) show an extremely large gap in the reported duration of symptoms, ranging from a few hours to 15 years from the first report of neurologic disturbance (mean duration: 27.2 ± 44.6 months). One patient \[[@CR7]\] presented acutely in the emergency room secondary to intratumoral bleeding, which led to sudden obstructive hydrocephalus. A plausible explanation is that this tumor might have an extremely indolent growth that patients do not recognize or report symptoms, except in cases of inherent tumoral complications (e.g. infarction, hemorrhage). The brain MRIs show most consistently solid-cystic changes (54.5%) that are iso/hypointense on T1-weighted images and hyperintense on T2-weighted images and with high probability of enhancement (whether ring-enhancement or heterogenous pattern, 65.9%; Table [1](#Tab1){ref-type="table"}). Average size was 30.3 ± 16.8 mm in the 29 cases with available information. Eleven patients (25%) showed calcifications while satellite lesions were noted in seven patients. Multiple lesions were extremely rare occurrences.

RGNT is a newly recognized CNS tumor having biphasic histologic characteristics \[[@CR1], [@CR30], [@CR31]\]. The key features \[[@CR2]\], described in virtually all the reports, include: (i) a neurocytic component composed of neurocytes forming rosettes (resembling Homer-Wright rosettes) around a synaptophysin-positive eosinophilic core and/or perivascular pseudorosettes that are arranged in arrays towards a vessel and (ii) an astrocytic component that is frequently described as closely resembling that of a pilocytic astrocytoma. A microcystic, myxoid matrix may be found in these neurocytic structures, while oligodendroglia-like cells (OLCs) may be seen in areas of the glial component. It has been reported that these OLCs have strong synaptophysin and Olig2 reactivity; however, they do not show 1p/19q co-deletion \[[@CR12]\]. Olig2, a transcription factor that controls development and differentiation of oligodendrocytes, is known to have variable expression in oligodendrocytes, oligodendrogliomas, neuroepithelial tumors and other glioneuronal tumors \[[@CR32]--[@CR34]\]. In our review, Rosenthal fibers and EGBs are each present in over 60% of cases. Nearly 1/2 of cases have hyalinized blood vessels and myxoid stroma. In 1/3 of cases microcalcifications are noted (Table [3](#Tab3){ref-type="table"}). "Dysmorphic" ganglion cells are reported in five cases \[[@CR4], [@CR5]\]. "Floating" Purkinje cells are specified in three cases \[[@CR3], [@CR29]\]. Whether the reported "dysmorphic" ganglion cells are also "floating" Purkinje cells remain to be clarified. Mitoses and necrosis are generally absent. No ganglion cells were identified in our illustrative case. Neither the neurocytic nor the astrocytic cellular component shows atypia.Table 3Additional histologic features seen in rosette-forming glioneuronal tumor casesPathologic findingFrequency (%)Rosenthal fibers29 (65.9)Eosinophilic granular bodies24 (64.5)Myxoid stroma21 (47.7)Hyalinized vessels19 (43.2)Microcalcification13 (29.5)Neurons9 (20.4)Hemorrhage5 (11.4)Hemosiderin4 (9.1)Vascular endothelial hyperplasia4 (9.1)

The immunohistochemical profile in our case is compatible with the previously published cases. Consistently described is immunoreactivity for synaptophysin in the neurocytic rosettes and perivascular pseudorosettes. Microtubule associated protein 2 (MAP2) and neuron specific enolase have also been reported to be expressed in the neurocytic cell processes. GFAP and S-100 immunoreactivity are variably present in the glial component, but are absent in the neurocytic component. Ki-67 labelling index is generally low, similar to the observation in our case (\<1%). Review of cases with available information shows a mean Ki-67 index of 1.8 ± 0.75 (SD) (range: 0--3.8%).

RGNTs have been suggested to arise from cells of the subependymal plate (periventricular germinal matrix) \[[@CR4]\] which have also been suggested as the site of origin of DNETs of the cerebellum \[[@CR1]\]. Whether this finding reflects normal or aberrant developmental placement of precursor or stem cells is uncertain. Increasing numbers of RGNTs have been recognized in locations other than the fourth ventricle. The alternate possibility of histologically similar tumors with underlying genetic differences is not excluded.

Genetics of RGNT {#Sec13}
----------------

Genetic abnormalities have not been well characterized in RGNT though they have been found in other glioneuronal tumors \[[@CR35]--[@CR38]\]. Due to very limited sample tissue availability in this case and given that chromosomes 1p/19q and Olig2 gene have been previously studied, we chose only to evaluate for IDH1 and 2 mutations.

*IDH1* is a gene encoding cytosolic NADP + -dependent isocitrate dehydrogenase, an enzyme that catalyzes oxidative decarboxylation of isocitrate to alpha-ketoglutarate. A hotspot mutation is located at position 395 (R132). R172 in exon 4 of IDH2 has the analogous function of R132 of IDH1 and is similarly a mutational hotspot in the gene. It is also suggested that *IDH* mutation is an early marker for tumorigenesis of diffuse gliomas as it tends to occur earlier than mutation of other genes including *TP53, PTEN*, and *EGFR* \[[@CR14], [@CR15]\], but is non-existent or rare in other types of brain tumors including gangliogliomas.

To date, genetic studies performed on RGNT is limited to evaluation for 1p19q loss \[[@CR12]\] and neurofibromatosis type 1 (NF1) gene deletion in chromosome 17 \[[@CR10]\] by fluorescent in situ hybridization; both of which were intact in this low grade neoplasm. Our finding of wild type IDH1 and IDH2 genotypes in RGNT are consistent with prior observations that mutations of those genes are relatively specific for diffuse gliomas. Nevertheless, more work is required to establish whether this finding is typical of RGNT in general or pertinent to pineal RGNTs only.

Treatment and prognosis {#Sec14}
-----------------------

The benign nature of this tumor has been repeatedly documented in most published studies. Despite a sizable number of cases (43 documented), gross total or subtotal resection (56.8% and 34% of cases respectively) appears to be effective in treating this tumor, with excellent outcome and with relatively little post-operative morbidity (Table [1](#Tab1){ref-type="table"}). Even patients who underwent biopsy alone remained stable with 1--2 year follow up \[[@CR8]\]. The majority of the cases did well post-operatively, with over a half of the cases (51.4%) having an unremarkable course or transient symptoms (14.3%). Documented post-operative morbidities include: ataxia (20%), cranial nerve palsy (17.1%) and others---including isolated cases of dysmetria, dysphagia, mutism, aggravation of presenting symptoms, and amenorrhea (in our case, which was likely a complication of chronic hydrocephalus). One patient who presented with disseminated intraventricular RGNT \[[@CR12]\] was stable after radiotherapy (46 Gy). One patient \[[@CR4]\], after subtotal resection and radiotherapy (5,500 cGy), died after 4 years, shortly after developing progressive brainstem symptoms and a ring enhancing lesion near the operative site. However, no autopsy was performed and the lesion was attributed to brainstem "radionecrosis". Only one case out of 35 (2.9%) with follow up recurred and did so after 10 years (mean follow-up (months): 30.3 ± 35.6) ---see Table [1](#Tab1){ref-type="table"}. Apart from post-surgical changes, the recurrence showed the typical RGNT histology. The value of treatment with radiation of RGNT is unclear owing to the scarcity of treated cases.

Conclusion {#Sec15}
==========

RGNT of the fourth ventricle is a distinct tumor entity that also arises in other locations of the CNS. Whether the tumor should be renamed will likely be a source of debate. The presence of Rosenthal fibers and EGBs in a piloid neoplasm involving the fourth ventricle or pineal region should prompt consideration of RGNT and a search for the typical neurocytic areas. We identify wildtype IDH1 and IDH2 genes but additional cases would be helpful to confirm this not unexpected genotype in RGNT. It should certainly be considered in the radiological differential diagnosis of solid-cystic tumors of the posterior fossa showing variable enhancement, with or without calcification. While the course is nearly always benign, the rare case of recurrence suggests that long-term follow up may be desirable.
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